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Amorphous solid dispersions (ASDs) of a poorly water-soluble active pharmaceutical ingredient (API) in a polymer 
matrix can enhance the water solubility and improve the bioavailability of the API. Many ASD products are kinetically 
stabilized, and the inhibition of crystallization of an API within and beyond shelf life is still a matter of debate, since the 
formation of crystals may impact bioavailability. We present the first literature examples of ASD long-term stability 
studies over up to 25 years under ambient storage conditions where no API crystallization was observed. Additionally, a 
risk assessment and mitigation strategy of API crystallization in packaged ASD drug products (DP) is outlined. The risk 
of shelf-life crystallization and the respective mitigation steps are assigned for different DP development scenarios. 
Ultimately, the physical stability of ASD DPs during shelf-life storage is modeled by quantifying crystal growth kinetics 
by transmission Raman spectroscopy (TRS), modeling the impact of water sorption on the glass-transition temperature 
of the ASD, and predicting the moisture uptake by the packaged ASD DP during storage. This approach is applied to an 
ASD of an AbbVie-internal compound showing stability beyond the anticipated shelf-life.  





Poor aqueous solubility and therefore scarcity of 
bioavailability of active pharmaceutical ingredients 
(APIs) is one of the main challenges in the development 
of solid oral dosage forms during the last few decades in 
the pharmaceutical industry.[1, 2] Formulating the API 
as an amorphous solid dispersion (ASD) has been 
proven to successfully enhance bioavailability of many 
APIs classified as biopharmaceutical classification 
system (BCS) class II and class IV.[3, 4] Many ASD 
formulations are thermodynamically unstable but 
kinetically stabilized due to low molecular mobility in 
the glassy ASD formulation.[5, 6] Accelerated API 
crystallization at high drug loads (DL) in kinetically 
stabilized ASDs is considered a potential risk for both, 
patients and pharmaceutical companies.[7] 
In this work the long-term physical stability of two 
kinetically stabilized ASDs is presented: a 15 %DL 
ASD of Fenofibrate was investigated after 15 years of 
storage under uncontrolled ambient conditions, and a 20 
%DL ASD of Nifedipine even after 25 years.[8, 9] 
Those observations show that even kinetically stabilized 
ASDs can be crystal free way beyond the desired 
pharmaceutical shelf-life. 
Additionally, a strategy for crystallization risk 
assessment of ASD products, based on monitoring 
crystal growth in ASDs using transmission Raman 
spectroscopy (TRS), is discussed. Our approach 
classifies the crystallization risk in the drug product 
(DP) based on accelerated open dish studies. Depending 
on the observed data, proper mitigation steps are 
advised. In case of an anticipated crystallization in the 
packaged DP over shelf-life, the actual crystal growth in 
the DP is estimated. For this step, open dish 
crystallization rates obtained at accelerated conditions 
are combined with modeling of the glass transition 
temperature Tg and water content of the packaged  DP 
during storage. 
RESEARCH CONCEPT 
One of the key factors in ASD formulations is the 




load of an oral dosage form is as high as possible from a 
commercial point of view because smaller dosage forms 
and lower pill burden are typically better tolerated.[10] 
A higher drug load in turn often reduces the physical 
stability of the ASD formulation in terms of API 
crystallization.[11] From a thermodynamic perspective, 
the API is dissolved in an amorphous polymeric matrix. 
However, in many ASD formulations, the API content 
exceeds its solubility in the matrix at storage conditions: 
the ASD is thermodynamically unstable but kinetically 
stabilized due to low molecular mobility in the glassy 
ASD.[5, 6] In general, by increasing the drug load in 
kinetically stabilized ASDs, the degree of 
supersaturation of the dissolved API in the matrix and, 
therefore, the thermodynamic driving force for API 
crystallization is increased.[12] In addition, many APIs 
have a lower glass-transition temperature (Tg) than the 
polymer, leading to reduced Tg of the ASD with 
increasing drug load (Figure 1).[8, 13] Such a decrease 
of Tg increases the molecular mobility and therefore 
reduces kinetic stabilization of the ASD.[14, 15] 
  
Figure 1: Exemplary phase diagram of a polymer-
fenofibrate system.[9] The solubility temperature at 
different compositions is depicted in blue. The measured 
Tg values of different compositions are depicted in red. 
The symbols reflect measured data and the curves show 
modeling results. Different regions can be identified in 
the phase diagram: (i) thermodynamically stable melt, 
(ii) thermodynamically stable glass, (iii) kinetically 
stable glass and (iv) the undercooled or unstable melt, 
respectively. 
The extend of stabilization and the required difference 
between storage temperature T and Tg of ASDs for 
avoiding API crystallization have been a matter of 
discussion in the literature for decades. As a rule of 
thumb, it has been assumed that a kinetically stabilized 
ASD needs to be stored at least 50 °C below Tg.[16] 
Assuming such an unnecessary high safety margin will 
hinder the development of high-drug load ASDs with 
low Tg. However, setting the safety margin to low will 
cause a potential patient safety risk. As a first measure 
to determine the physical stability of kinetically 
stabilized ASDs, long term stability studies have been 
conducted. In our studies we could show that no 
crystallization of the drug active is observed in ASDs of 
Nifedipine and Fenofibrate stored only 30 °C and even 
8 °C below Tg after 15 years and 25 years of storage, 
respectively.[8, 9]  
Despite those examples of long-term stability of 
kinetically stabilized ASDs, the demand for higher drug 
load and the occurrence of API crystallization in 
developmental stability studies makes it necessary for 
pharmaceutical development teams to have a proper risk 
assessment and mitigation strategy at hand. As time is 
of the essence in pharmaceutical development, we have 
developed a lean approach for API crystallization risk 
assessment in ASDs based on fast open dish studies, 
which excludes the patient risk of API crystallization 
over shelf-life storage while properly balancing the 
business risks involved (Figure 2).[17] 
The starting point of the risk assessment is the standard 
open dish stress test at 40 °C / 75% RH. Ifcrystallization 
is detected in this study within 14 days of storage, an 
investigation of the crystallization risk is indicated. As 
in this stage of development crystallization is usually 
detected qualitatively by polarized light microscopy, the 
next step is to quantify the crystal growth and assign a 
rate constant. This investigation is performed in a Tier I 
investigation, preferably using TRS. In our experience, 
the non-destructive nature, inherent sample averaging, 
and chemometric data evaluation make this technology 
more than suited to quantify crystal growth in ASD 
samples. From our work on long term stability, we can 
assume that an ASD taking 14 days or longer to show 
complete API crystallization in an open dish experiment 
at 40 °C / 75% RH will not present a crystallization risk 
during shelf-life storage of the packaged material.[9] In 
cases where the ASD under investigation shows a 
considerable crystallization rate, the physical stability of 
alternate formulations can be compared in a Tier II 
study. A Tier III investigation is indicated if no alternate 
formulation with sufficient stability is found, or other 
reasons, like bioavailability or manufacturability, 
indicate the usage of a formulation considered not 
physically stable. In the Tier III investigation, the 
crystallization rate constant is measured for several 
storage conditions above Tg. The rate constants can be 
correlated with the ratio of Tg over T. Calculations of the 
moisture dependence of the Tg in the ASD and moisture 
content of the packaged DP can be used to  determine 





Figure 2: Workflow of the physical shelf life modelling 
risk assessment strategy for crystallization in ASD 
formulations. An investigation of the physical stability 
is indicated if API crystallization is observed in the 
standard open dish stability investigation at 40 °C / 75% 
RH within two weeks. In a Tier I investigation, the rate 
of crystallization in the ASD is determined. If 
crystallization is sufficiently fast to indicate a shelf life 
risk, the crystal growth rate in alternate formulations is 
determined in a Tier II investigation. If no sufficiently 
stable formulation can be used, a Tier III investigation 
is indicated and the crystal growth of the DP in the 
primary packaging container is approximated.  
RESULTS 
The risk assessment strategy is now routinely applied to 
AbbVies ASD development candidates. The application 
of the complete risk assessment strategy on a model 
compound will be presented in this talk. After 
crystallization of the lead formulation candidate was 
observed in an open dish study, the rate of crystallization 
was determined and compared to alternate formulations 
(Figure 3). As the lead formulation had shown complete 
API crystallization within 3 days at 40 °C / 75% RH 
open dish condition, an estimation of the physical shelf-
life was indicated. Based on predicted water content of 
the blister packaged DP and calculated impact of water 
on the products Tg, a shelf-life till crystallinity limit of 
67 months could be estimated. 
 
Figure 3: Crystal growth in five different ASD 
formulation candidates of an AbbVie internal 
compound. The crystal growth was recorded in samples 
stored at 30 °C / 75 %RH (open dish) using TRS. The 
fraction of crystallized API normalized to total API is 
shown in dependence of time. 
DISCUSSION 
Our investigations of nifedipine and fenofibrate ASD 
DPs present, up to now, the only long-term stability 
investigations of kinetically stabilized ASDs in the 
literature and proved that such DPs can be safe over the 
shelf-life, even if stored only a few degrees below Tg. 
As crystallization still might occur in accelerated 
stability studies, pharmaceutical development teams 
require a strategy to assess and mitigate crystallization 
risk. An essential step in developing the presented fast 
risk assessment approach was determining the relation 
of the API crystallization rate with the environmental 
conditions. In the literature, different attempts can be 
found from simple Arrhenius extrapolation approaches 
to linking the crystallization with relaxation time in 
glasses. Utilizing recent glass physics approaches, we 
could successfully correlate the logarithm of the 
crystallization rate with the ratio of Tg over T. 
Combining this approach with the modeling of the water 
uptake of the packaged DP and the water induced 
change in Tg, we were able to estimate crystal growth in 
packaged DP based on fast open dish studies. Applying 
the risk assessment and mitigation strategy as presented 
in Figure 2 is aiding project development teams in 
making proper decisions regarding the crystallization 
risk of the ASD DP. In cases where crystallization of the 
API over the shelf-life is anticipated, a safe shelf-life 




With the results presented in this work, crystallization 




showstopper in ASD development. Using historical 
examples, the possibility of long-term stability in 
kinetically stabilized ASDs even if stored only a few 
degrees below Tg could be shown. Utilizing recent 
results of the investigation of glass physics in ASDs and 
combining them with physical modeling tools, a risk 
assessment and mitigation framework for API 
crystallization in ASD formulation could be developed. 
The framework enables drug development teams to 
conduct rational risk-based actions in ASD 
development. It allows to successfully bring ASD 
formulations to market that were just a couple of years 
ago discontinued due to perceived stability issues. 
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